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Abstract Germline mutations affecting the retinoblas-
toma gene (RB1) predispose to inherited retinoblastomas
but also other malignancies, including breast cancer. While
somatic RB1 mutations have been detected in different
malignancies, information about the potential role of RB1
mutations in breast cancer is limited. Recently, we dis-
covered RB1 mutations to be associated with resistance to
anthracyclines/mitomycin in primary breast cancer. The
present work is the ﬁrst report evaluating RB1 mutation and
epigenetic status in metastatic breast cancer. Among 148
breast cancer samples analyzed by MLPA, four samples
harbored intragenic deletions/duplications: Thus, exons
1–2 were deleted in two tumors and exons 21–23 in one
tumor, while one sample harbored duplication of exons
18–23. The entire RB1 gene was duplicated in two tumors
and multiple ampliﬁcations were revealed in one sample.
Reduced copy number was observed in 17 samples
(11.5%). No point mutation or promoter hypermethylation
was discovered (n = 38 and 114 tumors analyzed, respec-
tively).Interestingly,amongseventumorsexpressinglackof
response to epirubicin, two samples harbored alterations in
RB1,contrastingnoneoutof16tumorswithstablediseaseor
an objective response (P = 0.08). In summary, the fre-
quency of RB1 alterations in metastatic lesions was not
increased when compared to primary breast cancer, indi-
cating that RB1 alterations do not play a major role in met-
astatic development. While a non-signiﬁcant association
suggesting RB1 alterations to be linked to therapy resistance
was observed, our data do not suggest a major role for RB1
alterations explaining acquired drug resistance.
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Abbreviations
LOH Loss of heterozygosity
MLPA Multiplex ligation-dependent probe ampliﬁcation
PCR Polymerase chain reaction
pRb Retinoblastoma gene product
RB1 Retinoblastoma gene
Introduction
The retinoblastoma protein plays a key role regulating cell
cycle [1]. RB1 (the gene coding for the retinoblastoma
protein) has been found mutated in several types of cancer
[2–5], and germline mutations in the RB1 gene lead to
retinoblastomas, in general diagnosed within the ﬁrst year
of life [6].
Breast cancer is a heterogeneous category of tumors,
characterized by different classes of gene expression pro-
ﬁles [7]. However, while hundreds of genes may be
mutated, ampliﬁed or epigenetically deregulated, emerging
evidence suggests a limited number of gene alterations to
be responsible for malignant transformation as well as
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gene mutations into ‘‘drivers’’ versus ‘‘passengers’’ is
gaining increasing support [8–10]. Based on this hypothe-
sis, mutations affecting a limited number of genes (10–20
only) are considered to be of vital importance to tumor
propagation [10, 11]; mutations affecting other genes are
considered ‘‘passengers’’, generated randomly through
genetic instability without providing a growth advantage
under selection ‘‘pressure’’ in a tumor.
Emerging evidence suggests genes for which germline
mutations are associated with cancer risk (e.g., TP53,
CDKN2A, and RB1) often to be somatically inactivated in
sporadic tumors. While retinoblastoma survivors harboring
RB1 mutations are at enhanced risk of developing breast
cancer [12], the potential role of somatic RB1 gene defects
in breast cancer is poorly understood. While some studies
have reported loss of pRb immunostaining [13] or LOH
[14] in sporadic breast cancer, little is known with respect
to promoter methylation status. In a recent study, we found
three point mutations and two intragenetic deletions in a
total of 71 locally advanced primary breast cancers [15].
Moreover, three out of a total of four patients carrying such
mutations revealed resistance towards anthracycline- or
mitomycin-based chemotherapy.
Response rate to chemotherapy is lower in metastatic as
compared to primary breast cancer, and metastatic disease
inevitably progress towards a state of multidrug resistance
[16]. Based on its key role in regulating cellular growth [1]
and our recent ﬁndings of RB1 mutations associated with
drug resistance [15], we postulated mutated pRb protein to
be a ‘‘driver’’, providing a survival advantage for RB1-
mutated metastatic breast cancer cells. Thus, the aim of this
study was to evaluate the incidence of RB1 genetic and
epigenetic disturbances in metastatic breast cancer depos-
its. In addition, we correlated potential alterations to
response to anthracycline containing chemotherapy.
Materials and methods
Patients
All samples were collected from a secondary, metastatic
site in patients initially diagnosed with primary breast
cancer; this population does not overlap with the primary
breast cancer patients enrolled in our previous study [15].
Assembled information on adjuvant treatment following
surgery of primary tumor, treatment of metastatic disease
prior to biopsy, ER/PgR status, as well as localization of
metastatic deposits is provided for the patients in the core
cohort for which we performed complete gene sequencing
(35 out of 38 with available records) (Table 1) with
individual details for those patients harboring RB1 altera-
tions (Table 2).
Snap-frozen tumor samples were collected from a total
of 155 patients suffering form metastatic breast cancer.
From this cohort, 148 samples were analyzed for gene
dosage variation by MLPA, 114 samples for promoter
hypermethylation, while 38 samples were screened for
mutations throughout the open reading frame using RT-
PCR followed by complete sequencing (core cohort). All
patients gave written informed consent and the study was
approved by the Regional Ethical Committee. While
patients received different types of chemotherapy, RB1
status could be correlated to response to subsequent epi-
rubicin monotherapy (applied immediately after biopsy
collection) among 23 patients.
Table 1 Assembled characteristics and treatment of core cohort of
patients with available records (N = 35) suffering from metastatic
breast cancer included in the study
Patient characteristics
Median age at primary breast
cancer disease
47 years (range: 33–72)
Median time from primary
disease to relapse
35 months (range: 1–117)
Median time from ﬁrst
relapse to biopsy
1 month (range: 0-106)
ER/PgR status in the
primary setting
ER?: 18/31 patients
PgR?: 22/31 patients
Unknown ER/Pgr: 4 patients
ER/PgR status in the
metastatic setting
ER?: 5/17 patients
PgR?: 6/17 patients
Unknown ER/Pgr: 18 patients
Localization of metastatic
deposits
Locoregional: 32 patients
Distant locations: 3 patients
Treatment
Adjuvant therapy Tam: 13 patients
OETO: 4 patients
Chemotherapy (CMF): 13 patients
Radiotherapy: 13 patients
No treatment: 8 patients
For metastatic disease Tam: 11 patients
AI: 11 patients
OETO: 6 patients
Antracyclines: 11 patients
Other chemotherapy regimens
(FUMI, Tax, Xelo): 6 patients
Radiotherapy: 4 patients
No treatment: 16 patients
CMF Cyklofosfamid/metotrexate/5-ﬂuorouracil, Tam tamoxifen,
OETO other endocrine treatment option, FUMI 5-FU/mitomycin, Tax
taxol, Xelo xeloda, AI aromatase inhibitor, ER estrogen receptor, PgR
progesteron receptor
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123Genomic DNA puriﬁcation
Genomic DNA from tumor tissue was puriﬁed using the
QIAamp DNA Mini Kit (Qiagen) according to the manu-
facturer’s instructions.
RNA puriﬁcation and cDNA synthesis
Total RNA was puriﬁed from snap-frozen tumor biopsies
using Trizol (Life technologies) extraction and dissolved in
DEPC-treated deionised water. cDNA was synthesized by
reverse transcription using the Transcriptor reverse trans-
criptase system (Roche).
Analysis of promoter methylation
Genomic DNAs were subjected to bisulﬁte conversion
using the CpGenome DNA Modiﬁcation Kit (Intergen)
according to the manufacturer’s protocol and screened by
promoter methylation- and unmethylation-speciﬁc PCRs
(MSP and USP).
Table 2 Characteristics and treatment of patients with RB1 alterations in breast cancer metastases
RB1
aberrations
No of
samples
Patient Treatment ER/PgR status Localisation
of
metastatic
deposit
Adjuvant treatment For metastatic disease In primary
setting
In
metastatic
setting
Intragenic deletion
Exons 1–2 2/148 (1.4%) 172 CMF No treatment ER-/PgR- ER-/PgR- L
306 No treatment No treatment ER-/PgR- ER-/PgR- L
Exons
21–23
1/148 (0.7%) 419 Tam Adria, FUMI, Tax, Xelo ER-/PgR- ER-/PgR- L
Duplication
Exons
18–23
1/148 (0.7%) 121 Radiotherapy, CMF No treatment ER-/PgR? ER-/PgR– L
Exons 1–27 2/148 (1.4%) 312 Tam, OETO Adria, FUMI ER?/PgR? Unknown L
429 No treatment Tam, AI, Adria, FUMI ER?/PgR
?
ER-/PgR- L
Multiple ampliﬁcation
Exons 1–27 1/148 (0.7%) 431 No treatment Adria ER-/PgR- Unknown L
Allelic imbalance
Exons 1–27 17/148
(11.5%)
314 Radiotherapy, Tam AI, Adria ER?/PgR? Unknown L
143 Tam No treatment ER?/PgR? Unknown D
176 Tam, CMF OETO ER?/PgR? ER?/PgR? L
389 Tam, CMF Epi ER?/PgR? Unknown L
340 No treatment Tam Unknown Unknown L
005 Radiotherapy Adria ER?/PgR- ER?/PgR- D
137 Radiotherapy Tam, AI, OETO ER-/PgR? ER?/PgR- L
404 No treatment Radiotherapy, FUMI, Epi,
Tax
ER?/PgR? ER-/PgR- L
344 Adria Xelo Unknown Unknown L
339 No treatment Tam ER-/PgR- ER?/PgR- D
122 Radiotherapy, Tam,
CMF
Tam, Adria ER?/PgR- ER-/PgR- D
402-1 Tam Radiotherapy, AI ER?/PgR? ER?/PgR- L
315 No treatment No treatment ER-/PgR- ER-/PgR- L
305 Tam No treatment ER?/PgR? Unknown L
365 Tam AI, Adria, OETO ER?/PgR? Unknown D
182 No treatment No treatment ER?/PgR? ER?/PgR? D
184 Tam No treatment ER?/PgR? ER?/PgR- D
CMF cyklofosfamid/metotrexate/5-ﬂuorouracil, Tam tamoxifen, OETO other endocrine treatment option, Adria adriamycin, FUMI 5-FU/
mitomycin, Tax taxol, Xelo xeloda, AI aromatase inhibitor, Epi epirubicin, ER estrogen receptor, PgR progesteron receptor, L locoregional,
D distant location
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123Both the MSP and USP [17] were performed by an
initial 5 min DNA denaturation step at 95C followed by
35 cycles of 30 s at 94C, 30 s at 56.6C and 60 s at 72C
before a ﬁnal elongation step at 72C for 5 min. The 50 ll
reaction solution for both PCRs consisted of 2.5 U Amp-
liTaq Gold DNA Polymerase (Applied Biosystems), 19
PCR buffer, 1.5 mM MgCl2, 0.1 mM of each deoxynu-
cleotide triphosphate, 0.2 lM of each primer (Primers are
listed in Table 3), and 2 ll of modiﬁed genomic DNA.
Multiplex ligation-dependent probe ampliﬁcation
(MLPA)
MLPA analysis of 5 ll genomic DNA from 148 patients
was performed using SALSA MLPA RB1 kit (MRC Hol-
land, Amsterdam, The Netherlands) as previously descri-
bed [15]. The peak areas achieved using RB1 speciﬁc
probes in each patient sample was ﬁrst normalized by the
average of peak areas achieved by control probes speciﬁc
for locations different from chromosome 13. A corre-
sponding calculation was performed for two parallels of
pooled DNA from 10 healthy individuals. A ﬁnal ratio was
then calculated by dividing the value from the patient
samples by the matching value from the pool of healthy
individuals. If this ratio was below 0.75, the sample was
scored to have reduced copy number; If the ratio was above
1.25 the sample was scored as having increased copy
number. In addition, a negative sample (H2O) was included
in each run.
PCR ampliﬁcation of RB1 from cDNA
Ampliﬁcation of RB1 sequences using cDNA as template
was performed by nested PCR. In the ﬁrst round of PCR,
Table 3 RB1 genomic and cDNA primers
Sense primer Antisense primer Anneal.
temp.
(
oC)
RB1 Meth GGG AGT TTC GCG GAC GTG ACA C GT C G AAA CAC GCC CCG 56.6
RB1 Umeth GGG AGT TTT GTG GAT GTG ATA C AT C A AAA CAC ACC CCA 56.6
RB1 exon 2 GAT TAT TTT CAT TTG GTA GGC AAA GTG GTA GGA TTA CAG GC 52
RB1 exon 3 TTT TAA CAT AGT ATC CAG TGT GTG TAC ACT TTC ATA ACG GCT CC 54
RB1 exon 4 ACC CTT CGT TTT CTT ATA TTC TC ATC AGA GTG TAA CCC TAA TAA AAT G 55
RB1 exon 5 ATT GGG AAA ATC TAC TTG AAC TCA AAC TAA CCC TAA CTA TCA AG 54
RB1 exon 6 CAT TCT ATT ATG CAT TTA ACT AAG G CTA ACA GTT AAT AAG CCA AGC AG 54
RB1 exon 7 ATG GAT ATA CTC TAC CCT GCG ATC CTG TCA GCC TTA GAA CC 55.2
RB1 exon 8 GGA TGA AAT TGT TAT CCT TCT AAT GAA ACC GTA AAT ATT GTT AGG GAG AAC TTA CATC 60.7
RB1 exon 10 TCT TTA ATG AAA TCT GTG CCT CTG TG GAT ATC TAA AGG TCA CTA AGC TAA AGAC 60.7
RB1 exon 11 GAG ACA ACA GAA GCA TTA TAC TGC TGT GAT CCA CCA CAC CTG 60.7
RB1 exon 14 TGG GCA AAA CAG TGA GAC TCC GAT GCC TTG ACC TCC TGA TCT G 66.3
RB1 exon 15 TCA ATG CTG ACA CAA ATA AGG TTT C AAA TGT TGT CAT TCA GAA GTT TGC 60.7
RB1 exon 17 TTT CCT ATG AGT CCG TAG ACT CC GGT AGA TGT TAA GAA ACA CCT CTC AC 62.6
RB1 exon 18 GCC TAA AAT TCA TAG TAC TTA CCA TGT C ATG ACT TTA TTT GGG TCA TGT ACC 62.6
RB1 exon 21 GAT CAG TCC TGA ATA ATT GAG C CCT ATG TTA TGT TAT GGA TAT GG 52
RB1 exon 23 TAT GCT TCC ACC AGG GTA GGT C GCA AAT AGA GTT TCA AGA GTC TAG CTT AT 62.6
RB1 exon 27 CAG CCA CTT GCC AAC TTA C CAT AAA CAG AAC CTG GGA AAG 53.5
1r
RB1-1.r: A AAC GGG AGT CGG GAG AG GAA TTA TAT TCA CCT CTT CAT CAA G 45.0
RB1-1.r :B ATG ATA AAA CTC TTC AGA CTG ATT C TGT CCA CCA AGG TCC TGA G 45.0
2.r
RB1-2.r: A1 TCG GGA GAG GAC GGG GC CCA AGA AAC TTT TAG CAC CAA TG 58.0
RB1-2.r: A2 AGG AGG ACC CAG AGC AGG AC GAA GTC CAT TAG ATG TTA CAA GTC 53.0
RB1-2.r: A3 GTG CTA AAA GTT TCT TGG ATC CTC TTC ATC AAG GTT ACT TTT TCG T 58.0
RB1-2.r: B1 GAA ACA CAG AGA ACA CCA C ATT CTG AGA TGT ACT TCT GCT A 45.0
RB1-2.r: B2 AGC AAA CTT TGA ATG ACA AC GAG AGG TAG ATT TCA ATG G 45.0
RB1-2.r: B3 CTC CAA AGA AAA AAG GTT CAA GGT ATT GGT GAC AAG GTA GG 45.0
RB1-2.r: B4 GTA TTC TAT AAC TCG GTC TTC A TGT CCA CCA AGG TCC TGA G 45.0
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123two partly overlapping fragments designated A and B,
covering the complete reading frame of RB1, were ampli-
ﬁed under the following conditions: 94C for 5 min, 40
cycles at 94C for 30 s, 45C for 30 s and 72C for 2 min
and a ﬁnal extension at 72C for 4 min. In the second
round of PCR, the A and B fragments were used as tem-
plates to amplify the smaller products A1, A2, A3, B1, B2,
B3 and B4. The thermocycling conditions for the second
round PCRs were an initial step of 5 min denaturation at
94C followed by 40 cycles of 30 s at 94C, 30 s at opti-
mized annealing temperature and 60 s (A2, A3, B1, B2,
B3, and B4) or 20 s (A1) at 72C. As a ﬁnal extension step,
samples were incubated for 5 min at 72C. All primers and
annealing temperatures are listed in Table 3. Each PCR
was carried out in a 50 ll reaction solution consisting of
0.5 U Dynazyme EXT DNA polymerase, 19 PCR buffer,
5% DMSO, 0.2 mM of each deoxynuclotide triphosphate,
0.2 lM of each primer, and 20 ll cDNA (ﬁrst round of
ampliﬁcation) or 1 ll of corresponding ﬁrst-round PCR
product (second round of ampliﬁcation).
PCR ampliﬁcation of RB1 from genomic DNA
PCR ampliﬁcation of the RB1 exons 2, 3, 4, 5, 6, 7, 21, and
27 from genomic DNA was carried out using an initial
denaturation at 94C for 5 min, followed by 40 cycles at
94C for 30 s, optimized annealing temperature (Table 3)
for 30 s and 72C for 30 s. The ﬁnal elongation was carried
out at 72C for 5 min. The PCR ampliﬁcation of the exons
was performed in a 50 ll reaction solution consisting of 2.5
U AmpliTaq Gold DNA Polymerase (Applied Biosystems),
19 PCR buffer, 1.5 mM MgCl2, 0.1 mM of each deoxy-
nucleotide triphosphate, 0.2 lM of each primer (Table 3),
and 1 ll of genomic DNA.
PCR condition for ampliﬁcation of the RB1 exons 8, 10,
11, 14, 15, 17, 18, and 23 consisted of an initial 5 min
denaturationat94C,35cyclesof94Cfor1 min,optimized
annealing temperature (Table 3) for 5 s, and 72C for 10 s
followedbyaﬁnalstepat72Cfor7 min.Thereactionswere
carried out in a 25 ll solution containing 0.63 U KOD XL
DNA polymerase (Novagen), 19 PCR buffer, 0.2 mM of
each deoxynucleotide triphosphate, 0.2 lM of each primer
(Table 3), and 1 ll of genomic DNA.
TOPO-TA cloning of PCR products
For weak PCR products resulting in non-satisfactory
sequence quality, the reaction products were cloned into
the pCR 2.1 TOPO vector (Invitrogen) for individual
analysis. Resulting colonies were screened by amplifying
the insert using M13 PCR (according to the manufacturer’s
instructions). Colonies containing insert of correct length
were cultured and the corresponding plasmids were
puriﬁed by Qiagen spin miniprep kit (Qiagen) and
sequenced. A minimum of 10 individual clones were
sequenced from each sample.
DNA sequencing
DNA sequencing was performed directly on 1–5 ll of the
PCR products or plasmids using Big Dye terminator mix
(Applied Biosystems) and primers speciﬁc for each frag-
ment. An initial denaturation at 94C for 5 min was fol-
lowed by 40 cycles of 94C for 15 s, 50C for 5 s and 60C
for 4 min. Capillary gel electrophoresis, data collection and
sequence analysis were performed using an automated
DNA sequencer (ABI 3700, Perkin–Elmer Biosystems),
and the resulting sequences were compared with the RB1
wild-type sequence (GenBank accession number L11910).
Statistical analysis
Statistical calculations were performed using the SPSS
15.0 software and http://www.quantitativeskills.com/sisa/.
For Fisher exact tests, P-values are given as cumulative
and two-sided.
Results
Complete sequencing on cDNA was performed on 38
metastatic tumor deposits (core cohort). For some of the
tumor samples, it was not possible to obtain RT-PCR
products for a selection of the expected fragments. Thus,
we ampliﬁed the corresponding exons (2, 3, 4, 5, 6, 7, 21,
and 27) from genomic DNA. The complete RB1 reading
frame excluding exon 1 was analyzed in 35 samples. As for
the three remaining cases, the examination covered the
complete reading frame excluding exons 1–5 due to limited
tumor DNA in combination with high GC content causing
technical problems. Contrasting our previous ﬁndings in
non-matching primary breast cancer [15], no single point
mutation was discovered in any of the metastatic samples.
Due to the potential complication of nonsense mutations
and subsequent nonsense-mediated decay of RB1 mRNA,
our results were validated by analyzing exons 8, 10, 11, 14,
15, 17, 18 and 23 on genomic DNA from 28 out of 38
patients in the core cohort from whom DNA was available.
These exons were analyzed since they have the highest
frequencies of nonsense mutations in retinoblastoma
patients ([18] and http://rb1-lovd.d-lohmann.de/). In line
with our ﬁndings using RT-PCR screening, we observed no
mutations in these ‘‘hot spot’’ exons when analyzing the
same samples using genomic DNA, indicating that the
likelihood of any mutation escaping our cDNA sequencing
analyses are negligible.
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148 samples were analyzed for larger alterations in RB1 by
MLPA. We identiﬁed three tumors harboring intragenic
deletions (indels) (Table 2). Thus, exons 1–2 were found to
be deleted in two tumors (1.4%) and exons 21–23 deleted
in one (0.7%) sample (Fig. 1). Surprisingly, we detected
RBI duplications in several tumors (Table 2). One tumor
harbored a duplication of the exons 18–23, potentially
rupturing the full-length pRb protein if located within the
reading frame of RB1. Duplication of the entire RB1 locus
was observed in two samples (1.4%), while one tumor
showed multiple ampliﬁcations of the RB1 gene (0.7%). A
reduction of the RB1 gene copy number (LOH for the
entire locus) was observed in 17 of the samples (11.5%).
This was signiﬁcantly lower than the frequency previously
observed by us [15] in non-matching primary tumors (18/
71, 25%; P = 0.011).
Data presented in Tables 1 and 2 reveals that tumors
harboring RB1 alterations do not differ from tumors in the
core cohort with respect to parameters like pre-biopsy
treatment, receptor status and localization of metastatic
deposits.
A schematic representation of the RB1 deletions and
ampliﬁcations observed by MLPA in primary breast tumors
examined by us in our previous study [15] and metastatic
samples analyzed in this study is presented in Fig. 2.
While one of the patients with an exons 1–2 deletion and
the patient harboring the exons 21–23 deletion received
radiation therapy with non-evaluable response, the second
patient harboring exons 1–2 deletion and the tumor con-
taining exons 18–23 duplication both revealed lack of
response to epirubicin. Thus, two out of seven tumors
expressing resistance to epirubicin harbored alterations in
RBI, contrasting none out of 16 tumors with stable disease
or an objective response (P = 0.08, including patients
analyzed by MLPA and cDNA sequencing with available
clinical data on response). Interestingly, combining the
data from primary breast cancer [15] and the metastatic
samples analyzed in this study, we ﬁnd 5 out of 24 tumors
lacking response to anthracycline or mitomycin therapy to
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27 RB1 wild-type
RB1-exon 1-2
RB1-exon 21-23
RB1+exon 18-23
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27
18   19   20   21   22   23
A box B box Fig. 1 Schematic presentation
of RB1 alterations observed in
metastatic breast cancer
Primary Breast Cancer
WT
Allelic imbalance
Exon deletion
Duplication
Exon duplication
Multiple amplification
Metastatic Breast Cancer
WT
Exon deletion
Duplication
Exon duplication
Multiple amplification
Allelic imbalance
Fig. 2 Diagram showing the
distribution of RB1 deletions
and ampliﬁcations seen by us in
metastatic breast cancer lesions
analyzed in this study (bottom)
and primary breast cancer
samples (top) in a previous
study [15]
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123harbor RB1 point mutations or indels contrasting 1 out of
67 with response (P = 0.004).
None of the tumors analyzed revealed promoter hyper-
methylation (n = 114).
Discussion
Metastatic breast cancer inevitably progress towards mul-
tidrug resistance. Based on our recent ﬁndings of an
association between anthracycline/mitomycin resistance
and RB1 mutations in primary breast cancer [15], we
hypothesized that RB1 mutations may act as genetic
‘‘drivers’’, forcing tumor progression and therapy failure.
Here, we explored the hypothesis that alterations in RB1
could be enriched in metastatic compared to primary breast
cancers.
Contrary to our previous study of RB1 in non-matching
primary breast cancer [15], no point mutations were
observed in any of the metastatic breast cancer samples
analyzed in the present work. However, two different
intragenic deletions (indels) were found among three of the
148 metastatic lesions analyzed by MLPA. Our ﬁndings are
not at conﬂict with our previous results (three point
mutations and two indels in a total of 71 primary cancers),
but argue against the hypothesis that RB1 mutations may
act as ‘‘drivers’’ to the metastatic process as well as to
acquired drug resistance in metastatic breast cancer.
In our previous study of RB1 in primary breast cancer
[15], a total of three patients harbored a duplication of the
entire RB1 gene. To the best of our knowledge, this was the
ﬁrst time this type of alteration was described for RB1 in
breast cancer. As RB1 is a tumor suppressor, one would
expect that gene duplication would have an anti-tumori-
genic effect. However, the fact that the same phenomenon
reappeared together with a case of multiple ampliﬁcation of
the complete RB1 gene (which, to our knowledge has not
been described previously for RB1), in non-matching
metastatic breast lesions, indicates that duplications at the
RB1 locus are not anti-tumorigenic, but rather neutral or
potentially tumorigenic.
Although MLPA analysis does not provide information
about the exact location of the ampliﬁed region, we assume
the exons 18–23 duplication to be located intragenic, dis-
rupting the pRb protein function. This duplication was
observed in a patient expressing resistance to epirubicin.
Given that this alteration could rupture the full-length pRb
protein if located within the reading frame of RB1, two
tumors (one harboring exons 18–23 duplication and one
harboring exons 1–2 deletion) out of a total of seven
tumors expressing resistance to epirubicin harbored alter-
ations in RBI, contrasting none out of 16 tumors with stable
disease or an objective response (P = 0.08). Although the
number of samples are too limited for the data to reach
statistical signiﬁcance, these observations are in line with
our previous ﬁndings [15] suggesting that alterations in
RB1 could contribute to the development of chemotherapy
resistance in breast cancer.
Methylation of the RB1 promoter has been observed in
various human tumors including one study in breast car-
cinomas [17, 19, 20]. In the present study, which is the ﬁrst
to analyze for promoter methylation of RB1 in metastatic
breast cancer, we found no methylated tumors, indicating
that methylation of the promoter region of this gene is not a
key event in metastatic breast cancer. This ﬁnding is in
accordance with what we have previously described for
RB1 in locally advanced primary breast cancers [15].
We found the frequency of reduced RB1 gene copy
number to be lower among the metastatic lesions as com-
pared to what has been reported by others [14, 21, 22]a s
well as our own results reporting on non-matching primary
breast cancer [15]. This may seem as a paradox, since
deletion of a tumor suppressor in theory should provide
cells with growth advantages and support tumor progres-
sion (‘‘driver’’). Our present ﬁnding contrasts observations
in prostate carcinomas, in which the incidence of RB1 LOH
was found higher in metastatic as compared to primary
deposits [23]. However, our results are in line with the
observations of Ellsworth et al. reporting 25% allelic
imbalance for RB1 in primary breast tumor but 17% only in
matched axillary lymph node metastases [24]. To the best
of our knowledge, we are not aware of any other study
reporting RB1 allelic imbalance status in distant metastatic
breast cancer lesions. Whether reduced incidence of RB1
allelic imbalance in lymph node as well as distant metas-
tasis indicates clonal selection or presents an acquired
phenomenon [25] remains an open issue.
Taken together, we believe our studies of primary [15]
and metastatic breast cancer in combination add important
information in the quest to understand the role of RB1
alterations in breast cancer behavior. Although not
observed in corresponding patients, the ﬁnding that the
frequency of RB1 alterations did not increase from primary
to metastatic lesions argues against a major role for RB1
alterations as drivers during metastatic development. On
the other hand, genetic alterations disturbing RB1 function
seems to be associated with resistance towards anthracy-
cline therapy. Further studies are warranted to explore the
role of other genes involved in the same pathway [26]i n
anthracycline resistance among primary as well as meta-
static breast cancer.
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